(IN BRIEF) Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s disease, meeting primary endpoints in both the NEPTUNUS-1 and NEPTUNUS-2 trials. The treatment, which combines B-cell depletion and BAFF-R inhibition, … Read the full press release →
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged autoimmune disease, B cell depletion, BAFF-R inhibition, biopharmaceuticals, clinical trial results, ESSDAI, Fast Track Designation, ianalumab, immunology research, MorphoSys AG, NEPTUNUS-1, NEPTUNUS-2, Novartis, Shreeram Aradhye, Sjögren’s disease, systemic autoimmune disorder, targeted therapy, US FDA, VAY736